Medline ® Abstract for Reference 26
of 'Immunotherapy of advanced melanoma with immune checkpoint inhibition'
Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) (abstract LBA9003). 2014 American Society of Clinical Oncology (ASCO) meeting.
no abstract available